IS2808B - Mótefnasameindir sem eru með sérvirkni fyrir æxlisdrepboða alfa í mönnum og notkun þeirra - Google Patents

Mótefnasameindir sem eru með sérvirkni fyrir æxlisdrepboða alfa í mönnum og notkun þeirra

Info

Publication number
IS2808B
IS2808B IS6217A IS6217A IS2808B IS 2808 B IS2808 B IS 2808B IS 6217 A IS6217 A IS 6217A IS 6217 A IS6217 A IS 6217A IS 2808 B IS2808 B IS 2808B
Authority
IS
Iceland
Prior art keywords
antibodies specific
human tumor
alpha signaling
tumor alpha
signaling
Prior art date
Application number
IS6217A
Other languages
English (en)
Icelandic (is)
Other versions
IS6217A (is
Inventor
Diljeet Singh Athwal
Derek Thomas Brown
Andrew Neil Charles Weir
Andrew George Popplewell
Andrew Paul Chapman
David John King
Original Assignee
Ucb Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9893121&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS2808(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ucb Pharma Sa filed Critical Ucb Pharma Sa
Publication of IS6217A publication Critical patent/IS6217A/is
Publication of IS2808B publication Critical patent/IS2808B/is

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241Tumor Necrosis Factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6845Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6875Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Compression Of Band Width Or Redundancy In Fax (AREA)
IS6217A 2000-06-06 2002-01-03 Mótefnasameindir sem eru með sérvirkni fyrir æxlisdrepboða alfa í mönnum og notkun þeirra IS2808B (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0013810.7A GB0013810D0 (en) 2000-06-06 2000-06-06 Biological products
PCT/GB2001/002477 WO2001094585A1 (en) 2000-06-06 2001-06-05 Antibody molecules having specificity for human tumor necrosis factor alpha, and use thereof

Publications (2)

Publication Number Publication Date
IS6217A IS6217A (is) 2002-01-03
IS2808B true IS2808B (is) 2012-09-15

Family

ID=9893121

Family Applications (2)

Application Number Title Priority Date Filing Date
IS6217A IS2808B (is) 2000-06-06 2002-01-03 Mótefnasameindir sem eru með sérvirkni fyrir æxlisdrepboða alfa í mönnum og notkun þeirra
IS8986A IS3016B (is) 2000-06-06 2011-11-18 Mótefnasameindir sem eru með sérvirkni fyrir æxlisdrepsþátt alfa í mönnum og notkun þeirra

Family Applications After (1)

Application Number Title Priority Date Filing Date
IS8986A IS3016B (is) 2000-06-06 2011-11-18 Mótefnasameindir sem eru með sérvirkni fyrir æxlisdrepsþátt alfa í mönnum og notkun þeirra

Country Status (42)

Country Link
US (4) US7012135B2 (instruction)
EP (4) EP3059314B1 (instruction)
JP (3) JP4064812B2 (instruction)
KR (1) KR20020047097A (instruction)
CN (1) CN1289671C (instruction)
AP (1) AP2092A (instruction)
AR (1) AR033978A1 (instruction)
AT (1) ATE451460T1 (instruction)
AU (1) AU783756B2 (instruction)
BE (1) BE2010C019I2 (instruction)
BG (1) BG66072B1 (instruction)
BR (2) BR0106682A (instruction)
CA (2) CA2380298C (instruction)
CY (6) CY1109889T1 (instruction)
CZ (1) CZ300737B6 (instruction)
DE (3) DE122010000027I1 (instruction)
DK (4) DK2308975T3 (instruction)
EC (1) ECSP024210A (instruction)
ES (5) ES2230975B2 (instruction)
FR (1) FR10C0015I2 (instruction)
GB (2) GB0013810D0 (instruction)
HU (4) HU230561B1 (instruction)
IL (3) IL147992A0 (instruction)
IS (2) IS2808B (instruction)
LT (1) LT2308975T (instruction)
LU (1) LU91674I2 (instruction)
MX (1) MXPA01013440A (instruction)
MY (1) MY136603A (instruction)
NL (1) NL300982I9 (instruction)
NO (4) NO334808B1 (instruction)
NZ (1) NZ516596A (instruction)
OA (1) OA12282A (instruction)
PE (1) PE20020292A1 (instruction)
PL (2) PL218516B1 (instruction)
PT (4) PT2230308E (instruction)
RU (1) RU2303604C2 (instruction)
SI (3) SI1287140T1 (instruction)
SK (1) SK288343B6 (instruction)
TR (1) TR201900227T4 (instruction)
TW (2) TWI316088B (instruction)
WO (1) WO2001094585A1 (instruction)
ZA (1) ZA200200097B (instruction)

Families Citing this family (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0013810D0 (en) 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
CA2868614A1 (en) 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
US20060073141A1 (en) * 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
GB0129105D0 (en) * 2001-12-05 2002-01-23 Celltech R&D Ltd Expression control using variable intergenic sequences
ES2358505T3 (es) * 2002-03-20 2011-05-11 Ucb Pharma, S.A. Métodos para analizar isómeros de disulfuro de anticuerpos.
US20040009172A1 (en) * 2002-04-26 2004-01-15 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
SI3127553T1 (sl) 2002-05-02 2022-02-28 Wyeth Holdings Llc Konjugati nosilca derivatov kaliheamicina
GB0210121D0 (en) * 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
EP1534753B1 (en) 2002-05-28 2011-08-03 UCB Pharma, S.A. Peg positional isomer of an anti-tnfalpha antibody (cdp870)
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
KR101283877B1 (ko) * 2002-07-19 2013-07-08 애브비 바이오테크놀로지 리미티드 TNFα 관련 질환의 치료
US20040091490A1 (en) * 2002-08-28 2004-05-13 Robert Johnson Stable pH optimized formulation of a modified antibody
AU2003276844A1 (en) * 2002-08-28 2004-03-19 Pharmacia Corporation Formulations of modified antibodies and methods of making the same
US20040105858A1 (en) * 2002-08-29 2004-06-03 Kim Joanne Young Hee Kwak Diagnosis and treatment of infertility
MY150740A (en) 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
CN101899106A (zh) 2002-10-29 2010-12-01 阿纳福公司 三聚细胞因子的三聚结合蛋白
WO2004050683A2 (en) 2002-12-02 2004-06-17 Abgenix, Inc. Antibodies directed to tumor necrosis factor and uses thereof
US7101978B2 (en) 2003-01-08 2006-09-05 Applied Molecular Evolution TNF-α binding molecules
AU2004205684A1 (en) * 2003-01-23 2004-08-05 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
GB0303337D0 (en) * 2003-02-13 2003-03-19 Celltech R&D Ltd Biological products
CA2515612A1 (en) * 2003-02-19 2004-09-02 Pharmacia Corporation Activated polyethylene glycol esters
WO2004098578A2 (en) * 2003-05-12 2004-11-18 Altana Pharma Ag Composition comprising a pde4 inhibitor and a tnf-alfa antagonist selected from infliximab, adalimumab, cdp870 and cdp517
CN1845938B (zh) * 2003-06-30 2010-05-26 杜门蒂斯有限公司 多肽
WO2005014649A2 (en) * 2003-08-08 2005-02-17 Pharmacia Corporation Method for the preparation of molecules having antibody activity
WO2005017162A2 (en) * 2003-08-13 2005-02-24 Sandoz Ag Expression vectors, transformed host cells and fermentation process for the production of recombinant polypeptides
WO2005017174A2 (en) * 2003-08-13 2005-02-24 Sandoz Ag Process for the purification of recombinant polypeptides
GB0319601D0 (en) * 2003-08-20 2003-09-24 Sandoz Ag Production process
KR100570422B1 (ko) * 2003-10-16 2006-04-11 한미약품 주식회사 대장균 분비서열을 이용하여 항체 단편을 분비·생산하는 발현벡터 및 이를 이용하여 항체 단편을 대량 생산하는 방법
CN100393748C (zh) * 2003-11-06 2008-06-11 上海中信国健药业有限公司 全人源肿瘤坏死因子抗体,其制备方法以及药物组合物
KR100772800B1 (ko) * 2003-11-17 2007-11-01 주식회사유한양행 인간 종양괴사인자 α를 인식하는 단일클론항체의가변영역 및 이를 코딩하는 유전자
US7435799B2 (en) 2004-01-08 2008-10-14 Applied Molecular Evolution TNF-α binding molecules
CN100427504C (zh) * 2004-06-02 2008-10-22 北京天广实生物技术有限公司 TNFα高亲和力嵌合抗体及其用途
JP2008504356A (ja) * 2004-06-30 2008-02-14 ドマンティス リミテッド 炎症性疾患を治療するための組成物及び方法
GB0425972D0 (en) * 2004-11-25 2004-12-29 Celltech R&D Ltd Biological products
US8022040B2 (en) * 2004-11-29 2011-09-20 The Regents Of The University Of California Hydroxyapatite-binding peptides for bone growth and inhibition
KR100971497B1 (ko) * 2004-12-29 2010-07-21 주식회사유한양행 인간 종양괴사인자-알파에 특이적으로 결합하는 인간화항체
CA2608728A1 (en) 2005-05-16 2006-11-23 Abbott Biotechnology Ltd. Use of tnfa inhibitor for treatment of erosive polyarthritis
JP5414271B2 (ja) * 2005-06-01 2014-02-12 アムゲン リサーチ (ミュンヘン) ゲーエムベーハー 抗il2抗体
DK2390267T3 (da) 2005-06-07 2013-08-26 Esbatech A Novartis Co Llc Stabile og opløselige antistoffer, der hæmmer TNF(alfa)
GB0520169D0 (en) 2005-10-04 2005-11-09 Celltech R&D Ltd Biological products
EP2004231A4 (en) * 2006-04-07 2013-07-10 Nektar Therapeutics CONJUGATES OF ANTI-TNF-ALPHA ANTIBODY
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
EP2666472A3 (en) * 2006-04-10 2014-04-02 Abbott Biotechnology Ltd Uses and compositions for treatment of psoriatic arthritis
WO2007120656A2 (en) 2006-04-10 2007-10-25 Abbott Biotechnology Ltd. Uses and compositions for treatment of rheumatoid arthritis
US20080131374A1 (en) * 2006-04-19 2008-06-05 Medich John R Uses and compositions for treatment of rheumatoid arthritis
RU2503463C2 (ru) 2006-07-03 2014-01-10 Чарльз Дэвид ЭДЕЙР Композиция для модулирования экспрессии молекул клеточной адгезии
EP1914242A1 (en) * 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
WO2008109462A2 (en) * 2007-03-02 2008-09-12 Farnam Companies, Inc. Sustained release pellets comprising wax-like material
EP2166844A4 (en) * 2007-06-07 2013-09-04 Evonik Corp DOSAGE FORMS WITH EXTENDED ACTION AND REDUCED MASS
US8999337B2 (en) 2007-06-11 2015-04-07 Abbvie Biotechnology Ltd. Methods for treating juvenile idiopathic arthritis by inhibition of TNFα
US8865875B2 (en) 2007-08-22 2014-10-21 Medarex, L.L.C. Site-specific attachment of drugs or other agents to engineered antibodies with C-terminal extensions
AU2009212079B2 (en) * 2008-02-05 2012-08-30 Delenex Therapeutics Ag Antigen-binding polypeptides against cartilage degeneration
EP2279207B1 (en) * 2008-05-07 2015-09-09 Argos Therapeutics, Inc. Humanized antibodies against human interferon-alpha
CN102076716A (zh) * 2008-06-25 2011-05-25 艾斯巴技术,爱尔康生物医药研究装置有限责任公司 抑制TNFα的稳定和可溶的抗体
CA3020290A1 (en) 2008-06-25 2009-12-30 Esbatech, An Alcon Biomedical Research Unit Llc Stable and soluble antibodies inhibiting vegf
EP3964526A1 (en) 2008-06-25 2022-03-09 Novartis AG Humanization of rabbit antibodies using a universal antibody framework
ES2677003T3 (es) 2008-06-25 2018-07-27 Esbatech, An Alcon Biomedical Research Unit Llc Humanización de anticuerpos de conejo utilizando un marco universal de anticuerpos
CN101684156B (zh) * 2008-09-27 2011-12-28 苏州工业园区晨健抗体组药物开发有限公司 人TNFα单克隆抗体、其PEG化纳米颗粒及其应用
US20110165063A1 (en) * 2009-01-29 2011-07-07 Abbott Laboratories Il-1 binding proteins
CA2749966A1 (en) * 2009-01-29 2010-08-05 Abbott Laboratories Il-1 binding proteins
HUE051430T2 (hu) 2009-07-10 2021-03-01 Ablynx Nv Eljárás variábilis domének elõállítására
CN102575241B (zh) 2009-09-24 2016-02-24 Ucb医药有限公司 细菌宿主菌株
EP3520816B1 (en) 2009-10-23 2022-08-31 Takeda Pharmaceutical Company Limited Anti-gcc antibody molecules and related compositions and methods
GB201000587D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial hoist strain
GB201000590D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial host strain
GB201000588D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial host strain
GB201000591D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial hoist strain
GB201001791D0 (en) 2010-02-03 2010-03-24 Ucb Pharma Sa Process for obtaining antibodies
AU2011223547B2 (en) 2010-03-04 2016-05-05 Vet Therapeutics, Inc. Monoclonal antibodies directed to CD52
US9616120B2 (en) 2010-03-04 2017-04-11 Vet Therapeutics, Inc. Monoclonal antibodies directed to CD20
RU2012147249A (ru) 2010-04-07 2014-05-20 Эббви Инк. TNF-α- СВЯЗЫВАЮЩИЕ БЕЛКИ
GB201012599D0 (en) 2010-07-27 2010-09-08 Ucb Pharma Sa Process for purifying proteins
GB201012603D0 (en) 2010-07-27 2010-09-08 Ucb Pharma Sa Protein purification
GB201012784D0 (en) * 2010-07-29 2010-09-15 Ucb Pharma Sa Method
TWI538918B (zh) 2010-10-20 2016-06-21 財團法人工業技術研究院 人源化之單株抗體、其核苷酸序列與其用途
UY33679A (es) 2010-10-22 2012-03-30 Esbatech Anticuerpos estables y solubles
KR102066292B1 (ko) 2011-06-01 2020-01-14 인트랙슨 액토바이오틱스 엔.브이. 박테리아용 폴리시스트론 발현 시스템
HUE035674T2 (en) 2011-07-13 2018-05-28 Ucb Biopharma Sprl Bacterial host strain expressing recombinant dsbc
EP2546267A1 (en) 2011-07-13 2013-01-16 UCB Pharma S.A. Bacterial host strain expressing recombinant DsbC
HUE038336T2 (hu) 2011-09-23 2018-10-29 Intrexon Actobiotics Nv Módosított gram-pozitív baktériumok és alkalmazásaik
JP6117212B2 (ja) 2011-09-23 2017-04-19 イントレクソン・アクトバイオテイクス・エヌブイIntrexon Actobiotics NV 改変されたグラム陽性菌及びその使用
WO2013087911A1 (en) 2011-12-16 2013-06-20 Synthon Biopharmaceuticals B.V. Compounds and methods for treating inflammatory diseases
US9156915B2 (en) 2012-04-26 2015-10-13 Thomas Jefferson University Anti-GCC antibody molecules
GB201208367D0 (en) 2012-05-14 2012-06-27 Ucb Pharma Sa Biological product
US10113002B2 (en) 2012-08-13 2018-10-30 Genentech, Inc. Anti-jagged antibodies and methods of use
JP2017518737A (ja) 2014-04-21 2017-07-13 ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. SYK標的治療薬のための抗pSYK抗体分子及びその使用
EP3220961B1 (en) 2014-10-22 2023-07-05 Extend Biosciences, Inc. Therapeutic vitamin d conjugates
WO2016065052A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Insulin vitamin d conjugates
JP6807326B2 (ja) 2014-12-22 2021-01-06 ユーシービー バイオファルマ エスアールエル タンパク質製造方法
WO2017035430A2 (en) * 2015-08-27 2017-03-02 Kolltan Pharmaceuticals, Inc. Anti-alk antibodies and methods for use thereof
GB201522394D0 (en) 2015-12-18 2016-02-03 Ucb Biopharma Sprl Antibodies
JP7292877B2 (ja) 2016-01-14 2023-06-19 イントレクソン・アクトバイオテイクス・エヌブイ 1型糖尿病を処置するための組成物および方法
RU2680011C2 (ru) * 2016-04-29 2019-02-14 Закрытое Акционерное Общество "Биокад" Триспецифические антитела против il-17a, il-17f и другой провоспалительной молекулы
MX382216B (es) 2016-06-02 2025-03-13 Abbvie Inc Agonista del receptor de glucocorticoides e inmunoconjugados del mismo.
MA47106A (fr) 2016-12-21 2019-10-30 Amgen Inc Formulations d'anticorps anti-tnf alpha
CN111417410B (zh) 2017-12-01 2023-06-23 艾伯维公司 糖皮质激素受体激动剂及其免疫缀合物
WO2020157305A1 (en) 2019-01-31 2020-08-06 Numab Therapeutics AG Multispecific antibodies having specificity for tnfa and il-17a, antibodies targeting il-17a, and methods of use thereof
KR102323342B1 (ko) 2019-04-26 2021-11-08 주식회사 와이바이오로직스 IL-17A 및 TNF-α에 특이적으로 결합하는 이중표적 항체
CN111909268B (zh) * 2019-05-07 2022-04-19 北京天成新脉生物技术有限公司 低免疫原性低ADCC/CDC功能抗TNF-α人源化单克隆抗体TCX060及其应用
TW202237638A (zh) 2020-12-09 2022-10-01 日商武田藥品工業股份有限公司 烏苷酸環化酶c(gcc)抗原結合劑之組成物及其使用方法
TW202237639A (zh) 2020-12-09 2022-10-01 日商武田藥品工業股份有限公司 鳥苷酸環化酶c(gcc)抗原結合劑之組成物及其使用方法
MX2023009497A (es) 2021-02-15 2023-08-23 Takeda Pharmaceuticals Co Composiciones y metodos de terapia celular para modular la se?alizacion del factor de crecimiento transformador-beta (tgf-beta).
CN117500816B (zh) 2021-08-26 2025-03-28 映恩生物制药(苏州)有限公司 一种甾体化合物及其缀合物
CA3232722A1 (en) 2021-09-24 2023-03-30 Kiavash MIRZADEH Dna constructs and host cells for expressing recombinant protein
SE545694C2 (en) * 2021-09-24 2023-12-05 Xbrane Biopharma Ab Dna construct comprising nucleotide sequences encoding amino acid sequences of certolizumab and pelb signal peptides
SE545714C2 (en) * 2021-09-24 2023-12-19 Xbrane Biopharma Ab Dna contructs for producing a pelb signal peptide
WO2023154799A1 (en) 2022-02-14 2023-08-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Combination immunotherapy for treating cancer
AU2023353057A1 (en) 2022-09-30 2025-05-01 Extend Biosciences, Inc. Long-acting parathyroid hormone
WO2024180518A1 (en) * 2023-03-01 2024-09-06 Lupin Limited Process for manufacturing antibody fragment protein
WO2025049345A1 (en) 2023-08-25 2025-03-06 Proteologix Us Inc. Anti-il-13 multispecific antibody constructs and uses thereof
WO2025099576A1 (en) 2023-11-06 2025-05-15 Momenta Pharmaceuticals, Inc. Compositions and methods for treating rheumatoid arthritis

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
DK336987D0 (da) 1987-07-01 1987-07-01 Novo Industri As Immobiliseringsmetode
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8719042D0 (en) 1987-08-12 1987-09-16 Parker D Conjugate compounds
US5030570A (en) 1988-06-30 1991-07-09 The Eunice Kennedy Shriver Center For Mental Retardation DNA encoding and method of expressing human monoamine oxidase type A
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
PT92900A (pt) * 1989-01-24 1990-07-31 Sistema de vectores de expressao para a producao de anticorpos monoclonais quimericos
GB8907617D0 (en) 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
GB9109645D0 (en) * 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
US5919452A (en) 1991-03-18 1999-07-06 New York University Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
GB9120467D0 (en) 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
ES2138662T3 (es) * 1993-06-03 2000-01-16 Therapeutic Antibodies Inc Produccion de fragmentos de anticuerpos.
NO309690B1 (no) 1995-01-23 2001-03-12 Western Atlas Int Inc Detonasjonsanordning av type eksploderende brotråd for bruk med et perforeringsverktöy i en brönn
WO1996033204A1 (en) 1995-04-20 1996-10-24 The Kennedy Institute Of Rheumatology Multiple administrations of anti-tnf antibody
CN103275221B (zh) 1996-02-09 2016-08-17 艾伯维生物技术有限公司 结合人TNFα的人抗体
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
EP1015480A2 (en) * 1997-08-18 2000-07-05 Innogenetics N.V. Interferon-gamma-binding molecules for treating septic shock, cachexia, immune diseases and skin disorders
GB9720054D0 (en) * 1997-09-19 1997-11-19 Celltech Therapeutics Ltd Biological products
ATE399809T1 (de) 1998-03-12 2008-07-15 Nektar Therapeutics Al Corp Verfahren zur herstellung von polymerkonjugaten
GB9812545D0 (en) * 1998-06-10 1998-08-05 Celltech Therapeutics Ltd Biological products
GB0013810D0 (en) 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products

Also Published As

Publication number Publication date
HU230669B1 (hu) 2017-07-28
US7402662B2 (en) 2008-07-22
CY1109889T1 (el) 2012-01-25
DE60140738D1 (de) 2010-01-21
ZA200200097B (en) 2003-01-06
JP2007105043A (ja) 2007-04-26
EP1287140A1 (en) 2003-03-05
NL300982I9 (nl) 2019-05-06
AP2002002690A0 (en) 2002-12-31
ES2600080T3 (es) 2017-02-07
NO20020554D0 (no) 2002-02-04
JP5185143B2 (ja) 2013-04-17
EP2308975B1 (en) 2016-08-10
BRPI0106682B8 (pt) 2021-05-25
GB2366800B (en) 2005-01-19
CY2010011I2 (el) 2012-01-25
CZ300737B6 (cs) 2009-07-29
ES2230975B2 (es) 2007-04-16
BR0106682A (pt) 2002-05-14
IS6217A (is) 2002-01-03
TW200817430A (en) 2008-04-16
US7977464B2 (en) 2011-07-12
JP2009171966A (ja) 2009-08-06
FR10C0015I2 (fr) 2011-12-30
BRPI0106682B1 (pt) 2020-10-13
PE20020292A1 (es) 2002-05-08
BG106278A (bg) 2002-12-29
NL300982I1 (instruction) 2019-05-01
PT3059314T (pt) 2019-02-01
NZ516596A (en) 2004-07-30
JP2003535591A (ja) 2003-12-02
NO20020554L (no) 2002-04-08
JP4476989B2 (ja) 2010-06-09
MXPA01013440A (es) 2003-09-04
EP2230308A1 (en) 2010-09-22
ES2707714T3 (es) 2019-04-04
SI1287140T1 (sl) 2010-04-30
EP1287140B1 (en) 2009-12-09
EP3059314A1 (en) 2016-08-24
CY2019018I1 (el) 2020-05-29
ES2337763T3 (es) 2010-04-29
US20030026805A1 (en) 2003-02-06
IL195085A0 (en) 2009-08-03
SK288343B6 (sk) 2016-04-01
CA2707766C (en) 2013-05-21
LU91674I2 (fr) 2010-05-31
EP3059314B1 (en) 2018-10-24
NO20160694A1 (no) 2002-04-08
AP2092A (en) 2010-02-28
US7012135B2 (en) 2006-03-14
CA2380298C (en) 2010-09-28
CY2019018I2 (el) 2020-05-29
DK2308975T3 (da) 2016-10-31
CY1121173T1 (el) 2020-05-29
RU2303604C2 (ru) 2007-07-27
GB0013810D0 (en) 2000-07-26
IL147992A0 (en) 2002-09-12
AU6051101A (en) 2001-12-17
CY1114143T1 (el) 2016-07-27
CA2380298A1 (en) 2001-12-13
NO2014026I2 (no) 2018-02-14
HK1051385A1 (en) 2003-08-01
CA2707766A1 (en) 2001-12-13
PL353960A1 (en) 2003-12-15
HUP1600016A2 (en) 2002-10-28
LU91674I9 (instruction) 2019-01-03
ECSP024210A (es) 2002-05-23
PT2230308E (pt) 2013-05-03
WO2001094585A1 (en) 2001-12-13
TWI353358B (en) 2011-12-01
FR10C0015I1 (instruction) 2010-04-16
SK3152002A3 (en) 2002-07-02
HUS1700013I1 (hu) 2017-08-28
HUP0202346A3 (en) 2004-11-29
DK2230308T3 (da) 2013-05-06
JP4064812B2 (ja) 2008-03-19
MY136603A (en) 2008-10-31
NO2014026I1 (no) 2014-10-23
NO341218B1 (no) 2017-09-11
ES2403217T3 (es) 2013-05-16
US7186820B2 (en) 2007-03-06
SI2230308T1 (sl) 2013-06-28
US20020151682A1 (en) 2002-10-17
PL212738B1 (pl) 2012-11-30
NO339282B1 (no) 2016-11-21
SI2308975T1 (sl) 2016-11-30
TWI316088B (en) 2009-10-21
PT2308975T (pt) 2016-11-14
AR033978A1 (es) 2004-01-21
PL218516B1 (pl) 2014-12-31
ATE451460T1 (de) 2009-12-15
HUP1600483A2 (instruction) 2002-10-28
HU230561B1 (hu) 2016-12-28
LT2308975T (lt) 2016-11-10
US20080269465A1 (en) 2008-10-30
AU783756B2 (en) 2005-12-01
CZ2002837A3 (cs) 2002-05-15
CY2010011I1 (el) 2012-01-25
HU230553B1 (hu) 2016-11-28
KR20020047097A (ko) 2002-06-21
CY1118220T1 (el) 2017-06-28
EP2230308B1 (en) 2013-01-23
TR201900227T4 (tr) 2019-02-21
HK1148776A1 (en) 2011-09-16
GB2366800A (en) 2002-03-20
EP2308975A1 (en) 2011-04-13
DE122010000027I1 (de) 2010-08-12
GB0128386D0 (en) 2002-01-16
HUP0202346A2 (en) 2002-10-28
CN1289671C (zh) 2006-12-13
BG66072B1 (bg) 2011-01-31
PT1287140E (pt) 2010-03-08
PL399351A1 (pl) 2012-12-17
DK1287140T3 (da) 2010-04-19
NO20131316L (no) 2002-04-08
ES2230975A1 (es) 2005-05-01
NO334808B1 (no) 2014-06-02
BE2010C019I2 (instruction) 2020-08-20
OA12282A (en) 2006-05-11
IS3016B (is) 2019-10-15
CN1383450A (zh) 2002-12-04
US20060233800A1 (en) 2006-10-19
DK3059314T3 (en) 2019-02-18
IL147992A (en) 2009-06-15
DE10192353T1 (de) 2003-05-22

Similar Documents

Publication Publication Date Title
IS2808B (is) Mótefnasameindir sem eru með sérvirkni fyrir æxlisdrepboða alfa í mönnum og notkun þeirra
NO20004947D0 (no) Presipitert kalsiumkarbonat og fremstilling og anvendelse derav
DK1417175T3 (da) Substituerede dihydro-3-halo-1h-pyrazol-5-carboxylater og fremstillingog anvendelse heraf
DE60109600D1 (de) Gerillte quellen zur brachytherapie
IS6779A (is) Mannlíkt mótefni gegn LT-beta-R
IS2662B (is) Mótefni sem blokka prótínið Cripto og notkun þeirra
AU1166502A (en) Human ect2 and methods of use
PT2940044T (pt) Anticorpos anti-tnf alfa para utilização em terapia
IS2620B (is) Mennskgerð mótefni sem greina beta-amýlóíðpeptíð
NO20031653D0 (no) Metallkatalysator samt fremstilling og anvendelse derav
IS6965A (is) Ganglíósíð-tengd raðbrigða mótefni og notkun þeirra í sjúkdómsgreiningu og meðferð á æxlum
ATA12312001A (de) Lichtdurchlässiger flachkörper
DE60326190D1 (de) des Körpers
NO20044106L (no) Omkonstruerte baculoviruser og anvendelse derav
EE200200479A (et) Eksemestaani kasutamine rinnavähi ravis
AU2003255544A8 (en) Tumor specific oligosaccharide epitopes and use thereof
DE60221068D1 (de) Gerät zur tiefenwirksamen Hauttherapie
AU2002366195A8 (en) Use of bisindolmaleimide and gemcitabine for the treatment of cancer
ATA216498A (de) Einrichtung zur beleuchtung
LV12706B (lv) Piestatnu buvju rekonstrukcijas metode
IS6660A (is) Ný bispídínefnasambönd og notkun þeirra í meðhöndlun á hjartsláttarglöpum
EP1229795A4 (en) CHIMIOKINE BETA 13 HUMAN
ATE359288T1 (de) Silanylphenole und -naphthole
DE60228736D1 (de) Menschliches bmcc1-gen
SI1467707T1 (sl) Sestavek za lajsanje cloveskega poroda